Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...

Abstract #5038: Volixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: An Adaptive, Randomized, Placebo-controlled Phase 2b Trial (VANTAGE): Interim Results **Late-breaker poster ...

“Winter itch, also known as pruritus hiemalis, is a common type of dermatitis (skin irritation or inflammation) caused by ...

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals’ Third ...

Let’s dissect seven multiple sclerosis symptoms that Black people should recognize, and what they can do to address them.

FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter2024 to Discussthe Design of aCM-101 Accelerated Approval Phase 3Trial in Primary ...

Eun Lee, MD Itching (also known as pruritus) is a common symptom of diabetes, a chronic condition characterized by high blood ...

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has been assigned an average recommendation of “Hold” from the six ...

Equities researchers at StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a ...

Mirum Pharmaceuticals ( (MIRM) ) has released its Q3 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its ...